Evidence map›Paper›PMID 36514009›Full record

ArticleMolecular medicine (Cambridge, Mass.)2022

hUCMSCs carrying exenatide prevent T1DM by improving intestinal microflora composition and islet tissue damage repair.

Wei Wang, Yahao Wang, Jingwei Chi, Xiaojun Tan, Jianxia Hu, Xiaolong Ma, Xiaofang Sun, Kui Che, Wenshan Lv, Yangang Wang

Abstract read
In one paragraph

Article in Molecular medicine (Cambridge, Mass.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Wei WangDepartment of Hematology, The Affiliated Hospital of Qingdao University, Qingdao, 266000, People's Republic of China.
Yahao WangMedical College, Qingdao University, Qingdao, 266071, People's Republic of China.
Jingwei ChiKey Laboratory of Thyroid Diseases, Medical Research Center, The Affiliated Hospital of Qingdao University, Qingdao, 266000, People's Republic of China.
Xiaojun TanDepartment of Endocrinology, Yidu Central Hospital of Weifang City, Weifang, 261000, People's Republic of China.
Jianxia HuThe Laboratory of Thyroid Disease, The Affiliated Hospital of Qingdao University, Qingdao, 266000, People's Republic of China.
Xiaolong MaDepartment of Endocrinology, Liaocheng People's Hospital, Liaocheng, 252000, People's Republic of China.
Xiaofang SunDepartment of Endocrinology, The Affiliated Hospital of Qingdao University, No. 16, Jiangsu Road, South District, Qingdao, 266000, Shandong, People's Republic of China.
Kui CheKey Laboratory of Thyroid Diseases, Medical Research Center, The Affiliated Hospital of Qingdao University, Qingdao, 266000, People's Republic of China.
Wenshan LvDepartment of Endocrinology, The Affiliated Hospital of Qingdao University, No. 16, Jiangsu Road, South District, Qingdao, 266000, Shandong, People's Republic of China.
Yangang WangDepartment of Endocrinology, The Affiliated Hospital of Qingdao University, No. 16, Jiangsu Road, South District, Qingdao, 266000, Shandong, People's Republic of China. wangyg@qdu.edu.ORCID 0000-0003-2103-7729

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundExenatide is a stable analogue of glucagon-like peptide 1 that can reduce postprandial hyperglycemia and has been utilized as adjunctive therapy for type 1 diabetes mellitus (T1DM). The human umbilical cord is a rich source of MSCs, and human umbilical cord mesenchymal stem cells (hUCMSCs) also show potential to enhance insulin secretion. Here, we aimed to explore the effects of hUCMSCs carrying exenatide in T1DM and further identify the possible mechanisms involved.

methodshUCMSCs were isolated from human umbilical cord tissues, identified, and transduced with recombinant lentivirus carrying exenatide to obtain exenatide-carrying hUCMSCs (hUCMSCs@Ex-4).

resultsThe results showed that hUCMSCs@Ex-4 restored the blood glucose levels and body weight of NOD mice, and repressed immune cell infiltration and islet tissue changes. Additionally, in T1DM mice, treatment with hUCMSCs@Ex-4 reduced the blood glucose levels and promoted repair of islet tissue damage. Moreover, hUCMSCs@Ex-4 attenuated renal tissue lesions in T1DM mice. Applying bioinformatic analysis, the effects of hUCMSCs@Ex-4 were suggested to correlate with decreased abundance of pro-inflammatory intestinal bacteria and increased abundance of anti-inflammatory intestinal bacteria.

conclusionOverall, the study indicated that hUCMSCs carrying exenatide might improve beneficial intestinal microflora abundance and promote islet tissue damage repair, thereby alleviating T1DM.

Indexed as

Diabetes Mellitus, Type 1Gastrointestinal MicrobiomeMesenchymal Stem CellsAnimalsBlood GlucoseExenatideHumansMiceMice, Inbred NODBlood GlucoseExenatideExenatideHuman umbilical cord mesenchymal stem cellsIntestinal flora abundanceIslet tissue damageType 1 diabetes mellitus

Identifiers

PMID36514009
PMCPMC9746121

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.